Physician profile
Evan Mitchell Klass
NPI 1083785174
$333.37
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $62.31 · 2022: $16.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $65.96 | 2019 | |
| Tandem Diabetes Care, INC. | $46.07 | 2019-2020 | |
| Medtronic Minimed, INC. | $33.13 | 2019 | |
| Corcept Therapeutics | $24.69 | 2019 | |
| Antares Pharma, INC. | $23.91 | 2019 | |
| Abbvie INC. | $22.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.58 | 2020 | |
| Valeritas, INC. | $18.89 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.26 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.12 | 2019 | |
| Abbott Laboratories | $16.51 | 2022 | |
| Dexcom, INC. | $16.03 | 2020 | |
| Amgen INC. | $12.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Klass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.